ClinicalTrials.gg
CompletedNCT02149108Updated Jul 21, 2017Results posted

Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)

A Phase 3 interventional study of Nintedanib (BIBF 1120) and Placebo in Colorectal Neoplasms, sponsored by Boehringer Ingelheim. Completed at 129 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-21.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
768
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Colorectal Neoplasms by Boehringer Ingelheim — 1 open to participants now, 2 under way, none of them phase 3. Colorectal Neoplasms · Boehringer Ingelheim.

Enrollment
2nd of 14
768 · median 57
Started
2014
the only one that year
Phase 3
2 of 14
none open now
Registered
4th of 14
by date

Among the 14 studies in Colorectal Neoplasms by Boehringer Ingelheim, this one is the 2nd largest by enrollment, is the only one that started in 2014, is one of 2 in phase 3, and was the 4th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

1 of the 14 studies in Colorectal Neoplasms by Boehringer Ingelheim is open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Colorectal Neoplasms by Boehringer Ingelheim, or all of them as a file.
02

Study summary

The objective of this Phase III study is to evaluate the efficacy of nintedanib in patients with metastatic colorectal cancer (mCRC) after failure of previous treatment with standard chemotherapy and biological agents.

03

Conditions studied

  • Colorectal Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 18 years
  • Signed
  • or cytologically confirmed colorectal adenocarcinoma
  • or locally advanced disease not amenable to curative surgery and/or radiotherapy
  • (ECOG) performance status = 1
  • At least one according to (RECIST) version 1.1
  • Progression on standard therapies or withdrawn from standard treatment due to unacceptable toxicity. Previous standard treatment must include all of the following:
    • fluoropyrimidine
    • oxaliplatin: Patients treated with oxaliplatin in setting should have progressed within 6 months of completion of adjuvant therapy or they must have been treated with oxaliplatin for metastatic disease
    • irinotecan
    • bevacizumab or aflibercept
    • cetuximab or panitumumab for patients with K-Ras wt or Ras wt tumours
    • The remaining standard available therapy as recommended by investigator is best supportive care (note: previous treatment with regorafenib and TAS 102 are allowed and these agents should be administered before study if available to patient according to local standards)
    • of at least 12 weeks
    • Hepatic function: (AST)/ Alanine Amino Transferase (ALT) = 1.5 X (ULN) and = ULN for patients without liver metastases. AST/ALT = 2.5 X ULN and bilirubin = ULN for patients with liver metastases. Patients with Gilbert syndrome and bilirubin \< 2 X ULN and normal AST/ALT are eligible
  • Coagulation parameters: (INR) \< 2 and partial prothrombin Time (PTT) = 2xULN

Exclusion criteria

Exclusion criteria:

  • Previous treatment with nintedanib
  • toxicity attributed to previous anticancer therapy that did not resolve to (CTCAE) grade =1
  • History of other in the last 5 years, in particular those that could interfere with interpretation of results.
  • Serious concomitant disease or medical condition affecting compliance with trial requirements or which are considered relevant for the evaluation of the efficacy or safety of the trial drug,
  • Significant cardiovascular diseases
  • History of severe haemorrhagic or thromboembolic event in the past 12 months
  • Bleeding or thrombotic disorders requiring anticoagulant therapy such as warfarin, or similar agents requiring therapeutic monitoring
  • Gastrointestinal disorders or abnormalities that would interfere with absorption of study drug
  • Patient with that are symptomatic and/or require therapy.
  • Patients of who are sexually active and unwilling to use a highly effective method of
  • Pregnancy or breast-feeding.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
768 participants (actual)

Study arms

  • Experimental
    Nintedanib (BIBF 1120) + BSC

    Drug: Nintedanib (BIBF 1120) · Drug: BSC

  • Placebo comparator
    Placebo + BSC

    Drug: Placebo · Drug: BSC

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) by Central Review Assessment

    PFS by central review assessment was defined as the time from the date of randomisation to the date of disease progression according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 or death from any cause, whichever occurred first. Median, 95% Confidence Interval were calculated from an unadjusted Kaplan-Meier curve for each treatment arm.

    Time frame: From randomisation until cut-off date 14JUN2016.

  2. Overall Survival (OS)

    OS was defined as the time from randomisation to the time of death from any cause. Median, 95% Confidence Interval were calculated from an unadjusted Kaplan-Meier curve for each treatment arm.

    Time frame: From randomisation until cut-off date 14JUN2016.

Secondary outcomes

  1. Objective Tumour Response (Complete Response (CR)) + Partial Response (PR) by Central Review Assessment

    Objective tumour response was defined as best overall response of CR or PR determined by central review assessment.

    Time frame: From randomisation until cut-off date 14JUN2016.

  2. Disease Control (Complete Response + Partial Response + Stable Disease) by Central Review Assessment

    Disease control was defined as best overall response of CR, PR, or Stable Disease (SD).

    Time frame: From randomisation until cut-off date 14JUN2016.

07

Results

Posted Jul 21, 2017

Participant flow

The "completed" patients were on treatment (2 patients on Placebo, 3 patients on Nintedanib) at the data cut-off date 14JUN2016. The "NOT Completed" patients were off-treatment (380 patients on Placebo, 383 patients on Nintedanib) at the data cut-off date 14JUN2016.

Participant flow — Overall Study
MilestonePlaceboNintedanib
Started382386
Completed23
Not completed380383
Withdrew: Not treated12
Withdrew: Progressive disease (pd)324318
Withdrew: Worsening/adverse event cancer disease3132
Withdrew: Other adverse event (ae)818
Withdrew: Other not defined above02
Withdrew: Refusal to continue trial medication1511
Withdrew: Lost to follow-up10

Outcome measures

PrimaryProgression-Free Survival (PFS) by Central Review Assessment

PFS by central review assessment was defined as the time from the date of randomisation to the date of disease progression according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 or death from any cause, whichever occurred first. Median, 95% Confidence Interval were calculated from an unadjusted Kaplan-Meier curve for each treatment arm.

Time frame:
From randomisation until cut-off date 14JUN2016.
Reported as:
Median · Months
Progression-Free Survival (PFS) by Central Review Assessment
MonthsPlaceboNintedanib
Progression-Free Survival (PFS) by Central Review Assessment1.38 (1.38 to 1.41)1.51 (1.45 to 2.17)
Statistical analysis
  • Placebo vs Nintedanib · Log Rank · p = <0.0001 (Hazard ratio, confidence interval and p-value obtained from log-rank test stratified by regorafenib pre-treatment (yes vs no), time from onset metastatic disease until randomisation (less than 24 months vs 24 months or more ) and region.) · Hazard ratio (hr): 0.58 · 95% CI 0.49 to 0.69Hazard ratio \<1 favors Nintedanib.
PrimaryOverall Survival (OS)

OS was defined as the time from randomisation to the time of death from any cause. Median, 95% Confidence Interval were calculated from an unadjusted Kaplan-Meier curve for each treatment arm.

Time frame:
From randomisation until cut-off date 14JUN2016.
Reported as:
Median · Months
Overall Survival (OS)
MonthsPlaceboNintedanib
Overall Survival (OS)6.05 (5.22 to 6.97)6.44 (5.98 to 7.10)
Statistical analysis
  • Placebo vs Nintedanib · Log Rank · p = 0.8659 (Hazard ratio, confidence interval and p-value obtained from log-rank test stratified by regorafenib pre-treatment (yes vs no), time from onset metastatic disease until randomisation (less than 24 months vs 24 months or more ) and region.) · Hazard ratio (hr): 1.01 · 95% CI 0.86 to 1.19Hazard ratio below 1 favors Nintedanib.
SecondaryObjective Tumour Response (Complete Response (CR)) + Partial Response (PR) by Central Review Assessment

Objective tumour response was defined as best overall response of CR or PR determined by central review assessment.

Time frame:
From randomisation until cut-off date 14JUN2016.
Reported as:
Number · Percentage of participants
Objective Tumour Response (Complete Response (CR)) + Partial Response (PR) by Central Review Assessment
Percentage of participantsPlaceboNintedanib
Objective Tumour Response (Complete Response (CR)) + Partial Response (PR) by Central Review Assessment00
SecondaryDisease Control (Complete Response + Partial Response + Stable Disease) by Central Review Assessment

Disease control was defined as best overall response of CR, PR, or Stable Disease (SD).

Time frame:
From randomisation until cut-off date 14JUN2016.
Reported as:
Number · Percentage of participants
Disease Control (Complete Response + Partial Response + Stable Disease) by Central Review Assessment
Percentage of participantsPlaceboNintedanib
Disease Control (Complete Response + Partial Response + Stable Disease) by Central Review Assessment10.5 (3.68 to 6.67)25.6 (3.65 to 4.11)
Statistical analysis
  • Placebo vs Nintedanib · Regression, Logistic · p = <0.0001 (Odds ratio and p-value are obtained from logistic regression model adjusted for regorafenib pre-treatment (yes vs no), time from onset metastatic disease until randomization in the trial (less than 24 months vs. 24 months or more) and region.) · Odds ratio (or): 2.96 · 95% CI 2.00 to 4.47An odds ratio \>1 indicates benefit to Nintedanib.

Adverse events

Collected over From first drug administration until 28 days after last drug administration, up to 22.7 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—133/381 (34.9%)309/381 (81.1%)
Nintedanib—149/384 (38.8%)351/384 (91.4%)
Most frequent serious events
Showing 10 of 174
Most frequent serious events
EventPlaceboNintedanib
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)24/38127/384
DyspnoeaRespiratory, thoracic and mediastinal disorders12/38112/384
Alanine aminotransferase increasedInvestigations3/3817/384
Acute kidney injuryRenal and urinary disorders3/3817/384
Intestinal obstructionGastrointestinal disorders6/3816/384
Blood bilirubin increasedInvestigations6/3812/384
Pleural effusionRespiratory, thoracic and mediastinal disorders6/3813/384
Abdominal painGastrointestinal disorders4/3816/384
Urinary tract infectionInfections and infestations0/3816/384
Aspartate aminotransferase increasedInvestigations5/3816/384
Most frequent other events
Showing 10 of 27
Most frequent other events
EventPlaceboNintedanib
DiarrhoeaGastrointestinal disorders57/381175/384
NauseaGastrointestinal disorders103/381163/384
VomitingGastrointestinal disorders71/381149/384
Decreased appetiteMetabolism and nutrition disorders96/381128/384
FatigueGeneral disorders89/381113/384
Alanine aminotransferase increasedInvestigations23/38190/384
Aspartate aminotransferase increasedInvestigations44/38190/384
Abdominal painGastrointestinal disorders59/38165/384
ConstipationGastrointestinal disorders57/38165/384
AstheniaGeneral disorders46/38154/384

Baseline characteristics

Randomised Set (RS): This patient set included all patients who were randomised to receive treatment, whether treated or not.

Age, Continuous
Age, Continuous(Years)PlaceboNintedanibTotal
Mean61.1 ± 10.861.0 ± 11.361.1 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboNintedanibTotal
Female164150314
Male218236454
08

Study locations

129 sites
  • 1199.52.0108 Boehringer Ingelheim Investigational Site
    Los Angeles, California, United States
  • 1199.52.0105 Boehringer Ingelheim Investigational Site
    New Haven, Connecticut, United States
  • 1199.52.0101 Boehringer Ingelheim Investigational Site
    Plainville, Connecticut, United States
  • 1199.52.0121 Boehringer Ingelheim Investigational Site
    Arlington Heights, Illinois, United States
  • 1199.52.0123 Boehringer Ingelheim Investigational Site
    Sioux City, Iowa, United States
  • 1199.52.0104 Boehringer Ingelheim Investigational Site
    Topeka, Kansas, United States
  • 1199.52.0114 Boehringer Ingelheim Investigational Site
    New Orleans, Louisiana, United States
  • 1199.52.0113 Boehringer Ingelheim Investigational Site
    Detroit, Michigan, United States
  • 1199.52.0125 Boehringer Ingelheim Investigational Site
    Omaha, Nebraska, United States
  • 1199.52.0119 Boehringer Ingelheim Investigational Site
    Johnson City, New York, United States
  • 1199.52.0115 Boehringer Ingelheim Investigational Site
    Canton, Ohio, United States
  • 1199.52.0106 Boehringer Ingelheim Investigational Site
    Sylvania, Ohio, United States
  • 1199.52.0102 Boehringer Ingelheim Investigational Site
    Nashville, Tennessee, United States
  • 1199.52.0120 Boehringer Ingelheim Investigational Site
    Fort Worth, Texas, United States
  • 1199.52.5404 Boehringer Ingelheim Investigational Site
    Cdad. de Córdoba, Argentina
  • 1199.52.5405 Boehringer Ingelheim Investigational Site
    Cdad. de Córdoba, Argentina
  • 1199.52.5401 Boehringer Ingelheim Investigational Site
    Ciudad Autónoma de Bs As, Argentina
  • 1199.52.5403 Boehringer Ingelheim Investigational Site
    Ciudad Autónoma de Bs As, Argentina
  • 1199.52.5406 Boehringer Ingelheim Investigational Site
    Ciudad Autónoma de Bs As, Argentina
  • 1199.52.6102 Boehringer Ingelheim Investigational Site
    Concord, New South Wales, Australia
  • 1199.52.6103 Boehringer Ingelheim Investigational Site
    St Leonards, New South Wales, Australia
  • 1199.52.6101 Boehringer Ingelheim Investigational Site
    Wollongong, New South Wales, Australia
  • 1199.52.6104 Boehringer Ingelheim Investigational Site
    Heidelberg, Victoria, Australia
  • 1199.52.6105 Boehringer Ingelheim Investigational Site
    Nedlands, Western Australia, Australia
  • 1199.52.6106 Boehringer Ingelheim Investigational Site
    Perth, Western Australia, Australia
  • 1199.52.4302 Boehringer Ingelheim Investigational Site
    Linz, Austria
  • 1199.52.4303 Boehringer Ingelheim Investigational Site
    Wien, Austria
  • 1199.52.4304 Boehringer Ingelheim Investigational Site
    Wien, Austria
  • 1199.52.3208 Boehringer Ingelheim Investigational Site
    Aalst, Belgium
  • 1199.52.3205 Boehringer Ingelheim Investigational Site
    Bonheiden, Belgium
  • 1199.52.3202 Boehringer Ingelheim Investigational Site
    Bruxelles, Belgium
  • 1199.52.3207 Boehringer Ingelheim Investigational Site
    Charleroi, Belgium
  • 1199.52.3204 Boehringer Ingelheim Investigational Site
    Edegem, Belgium
  • 1199.52.3203 Boehringer Ingelheim Investigational Site
    Haine-Saint-Paul, Belgium
  • 1199.52.3201 Boehringer Ingelheim Investigational Site
    Leuven, Belgium
  • 1199.52.3206 Boehringer Ingelheim Investigational Site
    Liège, Belgium
  • 1199.52.3521 Boehringer Ingelheim Investigational Site
    Luxembourg, Belgium
  • 1199.52.1003 Boehringer Ingelheim Investigational Site
    Vancouver, British Columbia, Canada
  • 1199.52.1004 Boehringer Ingelheim Investigational Site
    Edmonton, Ontario, Canada
  • 1199.52.1001 Boehringer Ingelheim Investigational Site
    Toronto, Ontario, Canada
  • 1199.52.1002 Boehringer Ingelheim Investigational Site
    Montreal, Quebec, Canada
  • 1199.52.4202 Boehringer Ingelheim Investigational Site
    Brno, Czechia
  • 1199.52.4204 Boehringer Ingelheim Investigational Site
    Hradec Kralove, Czechia
  • 1199.52.4201 Boehringer Ingelheim Investigational Site
    Prague, Czechia
  • 1199.52.4502 Boehringer Ingelheim Investigational Site
    Herning, Denmark
  • 1199.52.4501 Boehringer Ingelheim Investigational Site
    København Ø, Denmark
  • 1199.52.4503 Boehringer Ingelheim Investigational Site
    Næstved, Denmark
  • 1199.52.4504 Boehringer Ingelheim Investigational Site
    Odense C, Denmark
  • 1199.52.3304 Boehringer Ingelheim Investigational Site
    Lille cedex, France
  • 1199.52.3307 Boehringer Ingelheim Investigational Site
    Lyon cedex 8, France
  • 1199.52.3305 Boehringer Ingelheim Investigational Site
    Paris cedex 15, France
  • 1199.52.3301 Boehringer Ingelheim Investigational Site
    Reims Cedex, France
  • 1199.52.4906 Boehringer Ingelheim Investigational Site
    Dresden, Germany
  • 1199.52.4905 Boehringer Ingelheim Investigational Site
    Essen, Germany
  • 1199.52.4904 Boehringer Ingelheim Investigational Site
    Freiburg, Germany
  • 1199.52.4903 Boehringer Ingelheim Investigational Site
    Mannheim, Germany
  • 1199.52.4901 Boehringer Ingelheim Investigational Site
    Ulm, Germany
  • 1199.52.8501 Boehringer Ingelheim Investigational Site
    Hong Kong, Hong Kong
  • 1199.52.8502 Boehringer Ingelheim Investigational Site
    Hong Kong, Hong Kong
  • 1199.52.8503 Boehringer Ingelheim Investigational Site
    Hong Kong, Hong Kong
  • 1199.52.8504 Boehringer Ingelheim Investigational Site
    Hong Kong, Hong Kong
  • 1199.52.9706 Boehringer Ingelheim Investigational Site
    Beer Sheva, Israel
  • 1199.52.9704 Boehringer Ingelheim Investigational Site
    Petach Tikva, Israel
  • 1199.52.9703 Boehringer Ingelheim Investigational Site
    Tel Aviv, Israel
  • 1199.52.3901 Boehringer Ingelheim Investigational Site
    Genova, Italy
  • 1199.52.3906 Boehringer Ingelheim Investigational Site
    Milano, Italy
  • 1199.52.3907 Boehringer Ingelheim Investigational Site
    Napoli, Italy
  • 1199.52.3905 Boehringer Ingelheim Investigational Site
    Padova, Italy
  • 1199.52.3903 Boehringer Ingelheim Investigational Site
    Pisa, Italy
  • 1199.52.3904 Boehringer Ingelheim Investigational Site
    San Giovanni Rotondo (FG), Italy
  • 1199.52.8102 Boehringer Ingelheim Investigational Site
    Aichi, Nagoya, Japan
  • 1199.52.8105 Boehringer Ingelheim Investigational Site
    Chiba, Chiba, Japan
  • 1199.52.8101 Boehringer Ingelheim Investigational Site
    Chiba, Kashiwa, Japan
  • 1199.52.8107 Boehringer Ingelheim Investigational Site
    Ehime, Matsuyama, Japan
  • 1199.52.8106 Boehringer Ingelheim Investigational Site
    Fukuoka, Fukuoka, Japan
  • 1199.52.8108 Boehringer Ingelheim Investigational Site
    Hokkaido, Sapporo, Japan
  • 1199.52.8115 Boehringer Ingelheim Investigational Site
    Hyogo, Amagasaki, Japan
  • 1199.52.8112 Boehringer Ingelheim Investigational Site
    Hyogo, Kobe, Japan
  • 1199.52.8114 Boehringer Ingelheim Investigational Site
    Ibaraki, Tsukuba, Japan
  • 1199.52.8110 Boehringer Ingelheim Investigational Site
    Oita, Yufu, Japan
  • 1199.52.8116 Boehringer Ingelheim Investigational Site
    Osaka, Osaka, Japan
  • 1199.52.8103 Boehringer Ingelheim Investigational Site
    Osaka, Suita, Japan
  • 1199.52.8109 Boehringer Ingelheim Investigational Site
    Saitama, Kitaadachi-gun, Japan
  • 1199.52.8104 Boehringer Ingelheim Investigational Site
    Shizuoka, Sunto-gun, Japan
  • 1199.52.8113 Boehringer Ingelheim Investigational Site
    Tokyo , Shinagawa-ku, Japan
  • 1199.52.8111 Boehringer Ingelheim Investigational Site
    Tokyo, Koto-ku, Japan
  • 1199.52.8202 Boehringer Ingelheim Investigational Site
    Goyang, Korea, Republic of
  • 1199.52.8201 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1199.52.8203 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1199.52.8204 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1199.52.5201 Boehringer Ingelheim Investigational Site
    Mexico, Mexico
  • 1199.52.3101 Boehringer Ingelheim Investigational Site
    Amsterdam, Netherlands
  • 1199.52.3103 Boehringer Ingelheim Investigational Site
    Amsterdam, Netherlands
  • 1199.52.3102 Boehringer Ingelheim Investigational Site
    Utrecht, Netherlands
  • 1199.52.4801 Boehringer Ingelheim Investigational Site
    Jelenia Gora, Poland
  • 1199.52.4803 Boehringer Ingelheim Investigational Site
    Poznan, Poland
  • 1199.52.4804 Boehringer Ingelheim Investigational Site
    Wroclaw, Poland
  • 1199.52.3504 Boehringer Ingelheim Investigational Site
    Almada, Portugal
  • 1199.52.3502 Boehringer Ingelheim Investigational Site
    Coimbra, Portugal
  • 1199.52.3505 Boehringer Ingelheim Investigational Site
    Loures, Portugal

Showing the first 100 of 129 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Van Cutsem E, Yoshino T, Lenz HJ, Lonardi S, Falcone A, Limon ML, Saunders M, Sobrero A, Park YS, Ferreiro R, Hong YS, Tomasek J, Taniguchi H, Ciardiello F, Stoehr J, Oum'Hamed Z, Vlassak S, Studeny M, Argiles G. Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. Ann Oncol. 2018 Sep 1;29(9):1955-1963. doi: 10.1093/annonc/mdy241. PubMed 30010751 ↗
  • Van Cutsem E, Yoshino T, Hocke J, Oum'Hamed Z, Studeny M, Tabernero J. Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment. Clin Colorectal Cancer. 2016 Mar;15(1):91-94.e1. doi: 10.1016/j.clcc.2015.09.005. Epub 2015 Oct 9. PubMed 26603056 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in May 2016, 19 months.

Results were first posted in Jul 2017, 1 year 2 months after primary completion.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 19 months is below that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2014
First posted
May 29, 2014
StartActual
Sep 25, 2014
Primary completionActual
May 13, 2016
CompletionActual
Aug 25, 2016
Results first posted
Jul 21, 2017
Last update
Jul 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02149108
Responsible party
Sponsor
First posted
May 29, 2014
Start date
Sep 25, 2014
Primary completion
May 13, 2016
Completion
Aug 25, 2016
Results posted
Jul 21, 2017
Last update
Jul 21, 2017

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion